| Symbol | IDRSF |
|---|---|
| Name | IDORSIA AG |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | 4123 Switzerland Hegenheimermattweg 91 |
| Telephone | +41 58 844 10 10 |
| Fax | — |
| — | |
| Website | https://www.idorsia.com |
| Incorporation | CH |
| Incorporated On | 2017 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: SIX Swiss Exchange |
| CIK | — |
| Description | Headquartered in Switzerland - a European biotech hub - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet - the ideal constellation to bringing R&D efforts to business success. Additional info from OTC: |
No news found.